A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

NCT03573960 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Neoplasms

Interventions

DRUG: Lenvatinib

Sponsor

Eisai Pharmaceuticals India Pvt. Ltd